Director Dealing
20/12/2022 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221220:nRST2390Ka&default-theme=true
RNS Number : 2390K Accrol Group Holdings PLC 20 December 2022
20 December 2022
This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the Company's obligations under Article 17 of
MAR.
Accrol Group Holdings plc
("Accrol" or the "Company")
Director Dealing
Accrol (AIM:ACRL), the UK's leading independent tissue convertor, has been
notified that Gareth Jenkins, the Chief Executive Officer, for personal
reasons, has sold 1,000,000 ordinary shares of £0.001 each ("Ordinary
Shares") at a price of 28.0 pence per Ordinary share.
Following this disposal, Gareth is interested in 4,422,929(1) Ordinary Shares
representing 1.39% of the issued share capital of the Company.
(1)3,741,346 of these Ordinary Shares are registered in the name of Gareth's
wife Susan Jenkins.
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Gareth Jenkins
2 Reason for the notification
a) Position/status CEO
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Accrol Group Holdings plc
b) LEI 213800MC56M5G69RJ226
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary shares of £0.001 each
Identification code
ISIN: GB00BZ6VT592
b) Nature of the transaction Sale of Ordinary shares
c) Price(s) and volume(s) Price(s) Volume(s)
£0.28 1,000,000
d) Date of the transaction 19 December 2022
e) Place of the transaction London Stock Exchange, AIM
d)
Date of the transaction
19 December 2022
e)
Place of the transaction
London Stock Exchange, AIM
For further information, please contact:
Accrol Group Holdings plc
Dan Wright, Executive Chairman Via Belvedere Communications
Gareth Jenkins, Chief Executive Officer
Richard Newman, Chief Financial Officer
Zeus (Nominated Adviser & Broker)
Dan Bate / Jordan Warburton Tel: +44 (0) 161 831 1512
Dominic King Tel: +44 (0) 203 829 5000
Liberum Capital Limited (Joint Broker) Tel: +44 (0) 20 3100 2222
Clayton Bush / Edward Thomas
Belvedere Communications Limited
Cat Valentine Tel: +44 (0) 7715 769 078
Keeley Clarke Tel: +44 (0) 7967 816 525
accrolpr@belvederepr.com (mailto:accrolpr@belvederepr.com)
Overview of Accrol
Accrol Group Holdings plc is a leading tissue converter and supplier of toilet
tissues, kitchen rolls, facial tissues, and wet wipes to many of the UK's
leading discounters and grocery retailers across the UK. The Group now
operates from six manufacturing sites, including four in Lancashire, which now
supplies 21.5% (volume) of the UK tissue market valued at £2.1bn at retail
sales value.
The Group has produced a short video to showcase its operations and investment
in the extensive automation of the business. Click here: Accrol Today
(https://vimeo.com/manage/videos/708603995/privacy) .
For more information, please visit www.accrol.co.uk (http://www.accrol.co.uk)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHFFFLIFALALIF